Efficacy and safety of warfarin therapy in patients with atrial fibrillation using genotype-guided dosing method
DOI:
https://doi.org/10.14739/2310-1210.2022.4.256945Keywords:
atrial fibrillation, warfarin, CYP2C9, CYP4F2, VKORC1, genetic polymorphism, pharmacogenetics, excessive hypocoagulation, bleedingAbstract
The aim. To evaluate the efficacy and safety of warfarin (WF) therapy in patients with atrial fibrillation (AF) using pharmacogenetic dosing method at an anticoagulant monitoring office according to the results of a one-year prospective follow-up.
Materials and methods. The study involved 110 patients with AF (mean age 68.72 ± 0.79; men – 57, women – 53). By the method of stratified randomization, the patients with AF were divided into two groups: the main group – 50 patients with AF and genotype-guided dosing method, the control group – 60 patients with AF and clinical dosing method. The outcomes were examined after the one-year follow-up: excessive hypocoagulation episodes (INR > 4) and bleeding. CYP2C9, CYP4F2, VKORC1 gene polymorphisms were determined using multiplex real time polymerase chain reaction; INR was controlled monthly; CHA2DS2-VASC, HAS-BLED, SAMe-TT2R2 scale scores were evaluated; TTR was calculated using the Rosendaal method.
Results. The distribution of CYP2C9, CYP4F2, VKORC1 genotypes in the main and control groups were in accordance with the Hardy–Weinberg equilibrium. In patients with AF and genotype-guided dosing, the frequency and risk of excessive hypocoagulation episodes (χ2 = 5.11; P < 0.05; RR = 0.50 (CI 0.27; 0.94)) and bleeding (χ2 = 9.57; P < 0.05; RR = 0.41 (CI 0.22; 0.77)) were significantly lower. However, the groups did not differ in TTR.
The validity of genetic-guided dosing was confirmed by the comparability of the medians and the direct correlation between the calculated and therapeutic WF doses (r = +0.57; P < 0.05). There were no relationships between TTR, excessive hypocoagulation episodes, hemorrhagic complications and clinical and genetic factors in the main group.
Conclusions. In patients with AF, the use of genotype-guided dosing method in the anticoagulant monitoring office helped to reduce the frequency and risk of excessive hypocoagulation episodes and bleeding as well as eliminate the influence of endogenous and exogenous factors in the personalized management of patients.
References
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G. A., Dilaveris, P. E., Fauchier, L., Filippatos, G., Kalman, J. M., La Meir, M., Lane, D. A., Lebeau, J. P., Lettino, M., Lip, G., Pinto, F. J., Thomas, G. N., … ESC Scientific Document Group (2021). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European heart journal, 42(5), 373-498. https://doi.org/10.1093/eurheartj/ehaa612
Jame, S., & Barnes, G. (2020). Stroke and thromboembolism prevention in atrial fibrillation. Heart, 106(1), 10-17. https://doi.org/10.1136/heartjnl-2019-314898
Gong, I. Y., Schwarz, U. I., Crown, N., Dresser, G. K., Lazo-Langner, A., Zou, G., Roden, D. M., Stein, C. M., Rodger, M., Wells, P. S., Kim, R. B., & Tirona, R. G. (2011). Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PloS one, 6(11), e27808. https://doi.org/10.1371/journal.pone.0027808
Vazquez, S. R. (2018). Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Hematology. American Society of Hematology. Education Program, 2018(1), 339-347. https://doi.org/10.1182/asheducation-2018.1.339
Danese, E., Raimondi, S., Montagnana, M., Tagetti, A., Langaee, T., Borgiani, P., Ciccacci, C., Carcas, A. J., Borobia, A. M., Tong, H. Y., Dávila-Fajardo, C., Rodrigues Botton, M., Bourgeois, S., Deloukas, P., Caldwell, M. D., Burmester, J. K., Berg, R. L., Cavallari, L. H., Drozda, K., Huang, M., … Fava, C. (2019). Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. Clinical pharmacology and therapeutics, 105(6), 1477-1491. https://doi.org/10.1002/cpt.1323
Sun, X., Yu, W. Y., Ma, W. L., Huang, L. H., & Yang, G. P. (2016). Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. Biomedical reports, 4(4), 498-506. https://doi.org/10.3892/br.2016.599
Al-Eitan, L. N., Almasri, A. Y., & Khasawneh, R. H. (2019). Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy. Saudi pharmaceutical journal : SPJ, 27(4), 484-490. https://doi.org/10.1016/j.jsps.2019.01.011
Kolesnyk, M. Y., & Mykhailovskyi, Y. M. (2021). Frequencies of polymorphisms in genes affecting the pharmacokinetics of warfarin in the Zaporizhzhia region. Zaporizhzhia Medical Journal, 23(4), 476-479. https://doi.org/10.14739/2310-1210.2021.4.227002
Asiimwe, I. G., Zhang, E. J., Osanlou, R., Jorgensen, A. L., & Pirmohamed, M. (2021). Warfarin dosing algorithms: A systematic review. British journal of clinical pharmacology, 87(4), 1717-1729. https://doi.org/10.1111/bcp.14608
Johnson, J. A., Caudle, K. E., Gong, L., Whirl-Carrillo, M., Stein, C. M., Scott, S. A., Lee, M. T., Gage, B. F., Kimmel, S. E., Perera, M. A., Anderson, J. L., Pirmohamed, M., Klein, T. E., Limdi, N. A., Cavallari, L. H., & Wadelius, M. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clinical pharmacology and therapeutics, 102(3), 397-404. https://doi.org/10.1002/cpt.668
Gage, B. F., Eby, C., Johnson, J. A., Deych, E., Rieder, M. J., Ridker, P. M., Milligan, P. E., Grice, G., Lenzini, P., Rettie, A. E., Aquilante, C. L., Grosso, L., Marsh, S., Langaee, T., Farnett, L. E., Voora, D., Veenstra, D. L., Glynn, R. J., Barrett, A., & McLeod, H. L. (2008). Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical pharmacology and therapeutics, 84(3), 326-331. https://doi.org/10.1038/clpt.2008.10
Eljilany, I., Elewa, H., & Al-Badriyeh, D. (2022). Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management. Current problems in cardiology, 101128. Advance online publication. https://doi.org/10.1016/j.cpcardiol.2022.101128
Zhu, Y., Moriarty, J. P., Swanson, K. M., Takahashi, P. Y., Bielinski, S. J., Weinshilboum, R., Wang, L., & Borah, B. J. (2021). A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?. Genetics in medicine, 23(3), 461-470. https://doi.org/10.1038/s41436-020-00995-w
Moloney, E., Craig, D., Holdsworth, N., & Smithson, J. (2019). Optimising clinical effectiveness and quality along the atrial fibrillation anticoagulation pathway: an economic analysis. BMC health services research, 19(1), 1007. https://doi.org/10.1186/s12913-019-4841-3
Zhang, J., Wu, T., Chen, W., Fu, J., Xia, X., & Chen, L. (2020). Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting. Frontiers in pharmacology, 10, 1527. https://doi.org/10.3389/fphar.2019.01527
Zhang, F., Zhang, C., Gu, C., Yu, Y., & Li, J. (2022). A clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement. BMC cardiovascular disorders, 22(1), 183. https://doi.org/10.1186/s12872-022-02620-x
Dahal, K., Sharma, S. P., Fung, E., Lee, J., Moore, J. H., Unterborn, J. N., & Williams, S. M. (2015). Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest, 148(3), 701-710. https://doi.org/10.1378/chest.14-2947
Shi, C., Yan, W., Wang, G., Wang, F., Li, Q., & Lin, N. (2015). Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PloS one, 10(12), e0144511. https://doi.org/10.1371/journal.pone.0144511
Tse, G., Gong, M., Li, G., Wong, S. H., Wu, W., Wong, W. T., Roever, L., Lee, A., Lip, G., Wong, M., Liu, T., & International Health Informatics Study (IHIS) Network (2018). Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. British journal of clinical pharmacology, 84(9), 1868-1882. https://doi.org/10.1111/bcp.13621
Jorgensen, A. L., Prince, C., Fitzgerald, G., Hanson, A., Downing, J., Reynolds, J., Zhang, J. E., Alfirevic, A., & Pirmohamed, M. (2019). Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC medicine, 17(1), 76. https://doi.org/10.1186/s12916-019-1308-7
Heneghan, C., Tyndel, S., Bankhead, C., Wan, Y., Keeling, D., Perera, R., & Ward, A. (2010). Optimal loading dose for the initiation of warfarin: a systematic review. BMC cardiovascular disorders, 10, 18. https://doi.org/10.1186/1471-2261-10-18
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J., & Briët, E. (1993). A method to determine the optimal intensity of oral anticoagulant therapy. Thrombosis and haemostasis, 69(3), 236-239.
Apostolakis, S., Sullivan, R. M., Olshansky, B., & Lip, G. (2013). Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest, 144(5), 1555-1563. https://doi.org/10.1378/chest.13-0054
Kolesnyk, M. Y., & Mykhailovskyi, Y. M. (2021). The interrelation of CYP2C9, CYP4F2, VKORC1 genes polymorphisms with warfarin dose and hemorrhagic complications risk rise in patients with atrial fibrillation: a retrospective study. East European science journal, 1(1), 37-43.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
